Head to Head Review: Aimei Health Technology (AFJK) and The Competition

Aimei Health Technology (NASDAQ:AFJK) is one of 89 publicly-traded companies in the “UNCLASSIFIED” industry, but how does it contrast to its competitors? We will compare Aimei Health Technology to related businesses based on the strength of its valuation, dividends, analyst recommendations, institutional ownership, profitability, earnings and risk.

Profitability

This table compares Aimei Health Technology and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aimei Health Technology	N/A	-95.88%	3.06%
Aimei Health Technology Competitors	0.86%	0.95%	0.80%

Earnings and Valuation

This table compares Aimei Health Technology and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aimei Health Technology	N/A	$2.55 million	54.35
Aimei Health Technology Competitors	$40.24 million	-$18.54 million	92.69

Aimei Health Technology’s competitors have higher revenue, but lower earnings than Aimei Health Technology. Aimei Health Technology is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aimei Health Technology and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aimei Health Technology	0	1	0	0	2.00
Aimei Health Technology Competitors	217	264	217	3	2.01

As a group, “UNCLASSIFIED” companies have a potential upside of 66.42%. Given Aimei Health Technology’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Aimei Health Technology has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

45.6% of Aimei Health Technology shares are owned by institutional investors. Comparatively, 51.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 2.5% of Aimei Health Technology shares are owned by insiders. Comparatively, 41.8% of shares of all “UNCLASSIFIED” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Aimei Health Technology has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Aimei Health Technology’s competitors have a beta of -0.08, meaning that their average stock price is 108% less volatile than the S&P 500.

Summary

Aimei Health Technology competitors beat Aimei Health Technology on 10 of the 13 factors compared.

About Aimei Health Technology

Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.